Vivimed Labs Declines 5.66% Amid Circuit Hits and Selling Pressure: 5 Key Factors Driving the Drop

31 August: Upper Circuit Triggered on Strong Buying Momentum

Vivimed Labs Ltd surged to its upper circuit limit at ₹7.21 on 31 August 2026, marking a 1.98% gain despite a broadly negative market where the Sensex declined 0.48%. This rally was driven by robust buying interest, with the stock recording gains for 11 consecutive sessions prior, delivering a cumulative return of 46.84%. The surge was accompanied by a healthy volume of 56,254 shares, signalling strong demand. However, the stock remained below its 200-day moving average, indicating longer-term caution among investors. The MarketsMOJO score remained at a concerning 17.0, categorised as Strong Sell, highlighting fundamental weaknesses despite the technical strength.

1 September: Sharp Reversal as Lower Circuit Hits Amid Panic Selling

The following day, Vivimed Labs reversed sharply, hitting its lower circuit limit at ₹6.80, a 1.88% loss. This decline was steeper than the sector’s 0.50% fall and the Sensex’s 0.30% drop, reflecting company-specific selling pressure. Trading volumes dropped to 21,110 shares, and delivery volumes surged on 31 August, suggesting sellers offloading positions amid deteriorating sentiment. The stock traded below its 5-day and 200-day moving averages, signalling short-term bearish momentum. The downgrade to a Strong Sell Mojo Grade likely contributed to the panic selling observed.

2 September: Continued Selling Pressure with Lower Circuit and Minimal Volumes

On 2 September, Vivimed Labs again hit the lower circuit at ₹6.67, losing 1.91%. The stock underperformed both the sector and Sensex, which fell 0.34% and 0.90% respectively. Trading volumes were exceptionally thin at just 21 shares, and delivery volumes plunged by 84.92%, indicating waning investor participation. Despite remaining above its 20-day, 50-day, and 100-day moving averages, the stock’s failure to hold above short-term averages reflected persistent weakness. The strong sell rating and micro-cap status intensified volatility and selling pressure.

3 September: Persistent Downtrend with Lower Circuit and Drying Volumes

Vivimed Labs continued its downward spiral on 3 September, hitting the lower circuit at ₹6.54, a 1.95% loss. This decline contrasted with a 0.40% gain in the Sensex and a marginal 0.08% sector decline, underscoring company-specific challenges. Trading volumes remained thin at 1,345 shares, with delivery volumes plunging 84.38%. The stock stayed above medium-term moving averages but below short-term and 200-day averages, reflecting mixed technical signals amid bearish momentum. The strong sell Mojo Grade and micro-cap vulnerabilities contributed to the ongoing selling pressure and investor caution.

4 September: Week Ends with Lower Circuit at ₹6.41 Amid Heavy Selling

The week closed on 4 September with Vivimed Labs hitting the lower circuit at ₹6.41, down 1.99%. This marked the fifth consecutive session of losses, cumulatively down 9.34%. The stock’s decline was stark against a 0.15% Sensex gain and a 0.18% sector fall, highlighting its underperformance. Trading volumes were subdued at 5,209 shares, with delivery volumes dropping 95.98%. The stock remained above intermediate moving averages but below short-term and 200-day averages, indicating fragile support. The persistent selling pressure and strong sell rating suggest continued near-term risks.

Daily Price Performance Compared to Sensex

Key Takeaways

1. Volatility and Circuit Hits: Vivimed Labs experienced extreme volatility with one upper circuit and four consecutive lower circuit hits, reflecting intense buying and selling pressures within a single week.

2. Underperformance vs Market: The stock declined 5.66% over the week, significantly underperforming the Sensex’s 1.11% fall, highlighting company-specific challenges beyond broader market trends.

3. Liquidity and Participation Concerns: Trading and delivery volumes contracted sharply during the week, signalling waning investor interest and increasing price volatility in this micro-cap stock.

4. Technical and Fundamental Signals: Despite some support from medium-term moving averages, the stock’s failure to hold short-term averages and a Strong Sell Mojo Grade indicate deteriorating fundamentals and bearish momentum.

5. Sector and Market Divergence: While the Pharmaceuticals & Drugs sector showed relative stability, Vivimed Labs’ sharp declines and circuit hits underscore company-specific risks and heightened investor caution.

Conclusion

Vivimed Labs Ltd’s week was marked by sharp swings and persistent selling pressure, culminating in a 5.66% weekly loss and multiple circuit breaker activations. The stock’s micro-cap status, combined with a Strong Sell rating and declining investor participation, has contributed to heightened volatility and underperformance relative to the broader market and sector. While some technical support exists at intermediate moving averages, the prevailing negative sentiment and fundamental concerns suggest continued caution. Investors should closely monitor upcoming corporate developments and market conditions before considering exposure to this stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →